Although pan-BET inhibitors are being tested in clinical trials for several different malignancies including lymphoma, breast cancer, and prostate cancer [12], the biological understanding of the different BET family members, especially BRD2, BRD3, and BRDT, in cancer is still very limited. Here, DNER is linked to prostate carcinoma.